Kaken Pharmaceutical（KKPC.F）株式概要科研製薬株式会社は、医療用医薬品、医療機器、農薬の製造・販売および国内外への販売を行っている。 詳細KKPC.F ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長3/6過去の実績0/6財務の健全性4/6配当金4/6報酬当社が推定した公正価値より2%で取引されている 収益は年間35.42%増加すると予測されています リスク分析株式の流動性は非常に低い 4.58%の配当は、利益やフリーキャッシュフローによって十分にカバーされていない すべてのリスクチェックを見るKKPC.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$26.0010.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-4b108b2016201920222025202620282031Revenue JP¥79.3bEarnings JP¥11.6bAdvancedSet Fair ValueView all narrativesKaken Pharmaceutical Co., Ltd. 競合他社Pacira BioSciencesSymbol: NasdaqGS:PCRXMarket cap: US$877.9mCollegium PharmaceuticalSymbol: NasdaqGS:COLLMarket cap: US$1.1bAmphastar PharmaceuticalsSymbol: NasdaqGS:AMPHMarket cap: US$785.7mWave Life SciencesSymbol: NasdaqGM:WVEMarket cap: US$1.2b価格と性能株価の高値、安値、推移の概要Kaken Pharmaceutical過去の株価現在の株価JP¥26.0052週高値JP¥28.1252週安値JP¥23.65ベータ0.151ヶ月の変化0%3ヶ月変化-7.54%1年変化n/a3年間の変化n/a5年間の変化-34.74%IPOからの変化193.84%最新ニュースお知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026お知らせ • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025最新情報をもっと見るRecent updatesお知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026お知らせ • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • May 12+ 3 more updatesKaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.お知らせ • Apr 11Kaken Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecast for Fiscal Year Ended March 31, 2025Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025.お知らせ • Mar 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the purchase agreement and stock purchase. Completion of the stock purchase is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the stock purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor and Leerink Partners LLC acted as Financial advisor to Aadi Bioscience, Inc. Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million on March 25, 2025.お知らせ • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025お知らせ • Feb 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 1,800,000 shares, representing 4.53% for ¥9,000 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock.お知らせ • Dec 22Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. Completion of the Stock Purchase is subject to customary closing conditions, including the approval of the Purchase Agreement and the Stock Purchase by the holders of a majority of the outstanding shares of Aadi’s capital stock entitled to vote to approve the Purchase Agreement and Stock Purchase, all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the Stock Purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor toお知らせ • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025お知らせ • Sep 03Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024お知らせ • Jun 26Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024お知らせ • May 16Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.お知らせ • Mar 03Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q4, 2024 results on May 09, 2024お知らせ • Dec 08Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 06, 2024お知らせ • Nov 15+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥176.92.お知らせ • Sep 19Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)お知らせ • Aug 30Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 08, 2023お知らせ • Aug 18+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided dividend forecast for second quarter of 2024 and fiscal year ending March 31, 2024. For the quarter, the company expects to pay a dividend of ¥75 against ¥75 paid last year.For the year, the company expects to pay a dividend of ¥75 against ¥75 paid last year.お知らせ • May 28Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023お知らせ • May 12Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.お知らせ • Dec 28Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 03, 2023株主還元KKPC.FUS PharmaceuticalsUS 市場7D0%-0.1%-0.3%1Yn/a38.7%26.7%株主還元を見る業界別リターン: KKPC.FがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: KKPC.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is KKPC.F's price volatile compared to industry and market?KKPC.F volatilityKKPC.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.0%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: KKPC.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のKKPC.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19171,126Hiroyuki Horiuchiwww.kaken.co.jp科研製薬(株)は、医療用医薬品、医療機器、農薬の製造・販売および国内外への販売を行っている。爪白癬外用剤「クレナフィン」、抗骨関節炎剤「アートス」、創傷治癒剤「フィブラスト」、原発性腋窩多汗症治療剤「エクロック」、歯周病再生剤「レグロス」、腰椎椎間板ヘルニア治療剤「ヘルニコール」、主に外科や婦人科で使用され、術後の癒着による合併症を軽減する癒着防止剤「セプラフィルム」などの医薬品や医療機器を提供している。また、殺菌剤として使用されるPolyoxins、稲用除草剤PentoxazoneとMetamifop、鶏用抗コクシジウム飼料添加物Salinomycinなどの農薬と動物用医薬品も提供している。さらに、エスチャーの除去を目的としたKMW-1、アタマジラミの治療薬として第III相臨床試験中のKAR、難治性血管奇形の治療薬として第II相臨床試験中のKP-001、原発性手掌足底多汗症の治療薬として第I相臨床試験中のBBI-4000を開発している；固形がんを対象とした第I相臨床試験中のKP-483、アトピー性皮膚炎を対象とした第I相臨床試験中のNM26-2198、末梢神経障害性疼痛を対象とした第I相臨床試験中のKP-910、原発性胆汁性胆管炎を対象とした第I相臨床試験中のSeladelpar、先天性副腎過形成を対象とした第I相臨床試験中のTildacerfontなどである。さらに、文京グリーンコートの賃貸にも携わっている。アルミス株式会社とは、皮膚科領域を適応症とする選択的経口次世代チロシンキナーゼ2（TYK2）阻害剤ESK-001の日本における開発、製造、商業化に関する提携およびライセンス契約を締結している。科研製薬株式会社は1917年に設立され、東京に本社を置いています。もっと見るKaken Pharmaceutical Co., Ltd. 基礎のまとめKaken Pharmaceutical の収益と売上を時価総額と比較するとどうか。KKPC.F 基礎統計学時価総額US$985.31m収益（TTM）-US$24.05m売上高(TTM)US$474.95m2.1xP/Sレシオ-41.0xPER（株価収益率KKPC.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計KKPC.F 損益計算書（TTM）収益JP¥75.66b売上原価JP¥35.49b売上総利益JP¥40.17bその他の費用JP¥44.00b収益-JP¥3.83b直近の収益報告Dec 31, 2025次回決算日May 13, 2026一株当たり利益（EPS）-101.19グロス・マージン53.09%純利益率-5.06%有利子負債／自己資本比率2.6%KKPC.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.6%現在の配当利回り-169%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/11 16:02終値2026/01/13 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kaken Pharmaceutical Co., Ltd. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Kazuaki HashiguchiDaiwa Securities Co. Ltd.Junya YamazakiJefferies LLCToshiyuki IwataMizuho Securities Co., Ltd.6 その他のアナリストを表示
お知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
お知らせ • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.
お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025
お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • May 13Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 26, 2026.
お知らせ • Apr 01Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
お知らせ • Dec 19Kaken Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
お知らせ • Sep 29Kaken Pharmaceutical Co., Ltd. Revises Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026Kaken Pharmaceutical Co., Ltd. revised consolidated financial forecast for fiscal year ending March 31, 2026. For the period, the company expects net sales of JPY 86,300 million compared to previous guidance of JPY 88,000 million, operating profit of JPY 2,100 million compared to previous guidance of JPY 5,200 million and profit attributable to owners of parent company of JPY 2,300 compared to previous guidance of JPY 3,400 million or basic earnings per share of JPY 60.74 per share compared to previous guidance of JPY 88.53.
お知らせ • Sep 11Kaken Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 10, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025
お知らせ • May 31Kaken Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • May 12+ 3 more updatesKaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.
お知らせ • Apr 11Kaken Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecast for Fiscal Year Ended March 31, 2025Kaken Pharmaceutical Co., Ltd. revised consolidated earnings forecast for fiscal year ended March 31, 2025. For the year, the company expected net sales of JPY 94,000 million compared to previous forecast of JPY 88,500 million; Operating profit of JPY 20,800 million compared to previous forecast of JPY 20,800 million; Profit attributable to owners of the parent of JPY 14,000 million compared to previous forecast of JPY 14,200 million and Basic earnings per share of JPY 364.55 compared to previous forecast of JPY 374.97. The forecast for net sales has been revised upward from the previously announced forecast to reflect the receipt of an upfront payment as described in the press release KAKEN Entered into a License Agreement for STAT6 Inhibitor announced on December 26, 2024, and other factors. Operating profit, ordinary profit, and profit attributable to owners of the parent have been partially revised to reflect the upfront payment as described in the press release Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan announced on March 25, 2025, as well as the expenses described in the press release Notice of Completion of Acquisition of Aadi Subsidiaries, Inc, U.S.A. announced on March 27, 2025.
お知らせ • Mar 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. The purchase price is subject to customary adjustments. The board of directors of Aadi approved and recommend that Aadi’s stockholders vote in favor of, and authorize the approval of, the purchase agreement and stock purchase. Completion of the stock purchase is subject to customary closing conditions, including all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the stock purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. On February 28, 2025, shareholders of Aadi Bioscience approved the transaction. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor and Leerink Partners LLC acted as Financial advisor to Aadi Bioscience, Inc. Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $102.4 million on March 25, 2025.
お知らせ • Mar 25Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025
お知らせ • Feb 26Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 1,800,000 shares, representing 4.53% for ¥9,000 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces a share repurchase program. Under the program, the company will repurchase 1,800,000 shares, representing 4.53% of its share capital, for ¥9,000 million. The purpose of the program is to strengthen shareholder returns and improve capital efficiency, as well as to address the dilution of shares resulting from the disposal of treasury stock. The program will run until September 30, 2025. As of January 31, 2025, the company had 39,758,792 shares in issue (excluding treasury stock) and 6,180,938 shares of treasury stock.
お知らせ • Dec 22Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million.Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. (NasdaqCM:AADI) for $100 million on December 19, 2024. Completion of the Stock Purchase is subject to customary closing conditions, including the approval of the Purchase Agreement and the Stock Purchase by the holders of a majority of the outstanding shares of Aadi’s capital stock entitled to vote to approve the Purchase Agreement and Stock Purchase, all consents and approvals required under certain regulatory laws having been obtained and the absence of any law or order preventing, materially restraining or materially impairing the consummation of the Stock Purchase. Completion of the Stock Purchase is also subject, with certain exception, to the completion of certain internal pre-closing restructuring transaction. In case of termination of transaction, Aadi Bioscience, Inc. will pay a termination fee of $3.50 million. The transaction is expected to close in the first half of 2025. Matt Carter and David A. Lipkin of McDermott Will & Emery LLP acted as legal advisor to Kaken Pharmaceutical Co., Ltd. Dan Koeppen, Robert L. Wernli, Jr., Ethan Lutske and Jack Hamilton of Wilson Sonsini Goodrich & Rosati acted as legal advisor to
お知らせ • Nov 30Kaken Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
お知らせ • Sep 03Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 08, 2024
お知らせ • Jun 26Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024
お知らせ • May 16Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.
お知らせ • Mar 03Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q4, 2024 results on May 09, 2024
お知らせ • Dec 08Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 06, 2024
お知らせ • Nov 15+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided consolidated financial forecast for fiscal year ending March 31, 2024. For the year, the company expects net sales of ¥73,100 million, operating profit of ¥7,600 million, profit attributable to owners of the company of ¥6,700 million and basic earnings per share of ¥176.92.
お知らせ • Sep 19Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)
お知らせ • Aug 30Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 08, 2023
お知らせ • Aug 18+ 1 more updateKaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024Kaken Pharmaceutical Co., Ltd. provided dividend forecast for second quarter of 2024 and fiscal year ending March 31, 2024. For the quarter, the company expects to pay a dividend of ¥75 against ¥75 paid last year.For the year, the company expects to pay a dividend of ¥75 against ¥75 paid last year.
お知らせ • May 28Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023
お知らせ • May 12Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.
お知らせ • Dec 28Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023Kaken Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 03, 2023
